Actelion's silver lining: macitentan dropped in IPF but safety data boost PAH hopes
This article was originally published in Scrip
Every cloud has a silver lining. For investors in Actelion, reporting results of an exploratory Phase II study of its targeted endothelin receptor antagonist macitentan in patients with idiopathic pulmonary fibrosis (IPF), the disappointment that the drug didn't reach its primary endpoint was more than offset by the safety and tolerability data reported. This is because those data could bolster the prospects for macitentan in pulmonary arterial hypertension (PAH), for which a Phase III study is scheduled to report in the first half of next year.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.